Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona, Ospedale Civile Maggiore, Piazzale Stefani, 1, 37126 Verona, Italy.
Atherosclerosis. 2010 Jun;210(2):575-80. doi: 10.1016/j.atherosclerosis.2009.12.008. Epub 2009 Dec 11.
There is limited and controversial information on whether anaemia is a risk factor for cardiovascular mortality in type 2 diabetes, and whether this risk is modified by the presence of chronic kidney disease (CKD). We assessed the predictive role of lower hemoglobin concentrations on all-cause and cardiovascular mortality in a cohort of type 2 diabetic individuals.
The cohort included 1153 type 2 diabetic outpatients, who were followed for a mean period of 4.9 years. The independent association of anaemia (i.e., hemoglobin <120 g/l in women and <130 g/l in men) with all-cause and cardiovascular mortality was evaluated by Cox proportional hazards regression models and adjusted for several potential confounders, including kidney function measures.
During follow-up, 166 (14.4%) patients died, 42.2% (n=70) of them from cardiovascular causes. In univariate analysis, anaemia was associated with increased risk of all-cause (hazard ratio HR 2.62, 95% confidence intervals 1.90-3.60, p<0.001) and cardiovascular mortality (HR 2.70, 1.67-4.37, p<0.001). After adjustment for age, sex, body mass index, smoking, hypertension, dyslipidemia, diabetes duration, hemoglobin A1c, medication use (hypoglycemic, anti-hypertensive, lipid-lowering and anti-platelet drugs) and kidney function measures, the association of anaemia with all-cause (adjusted HR 2.11, 1.32-3.35, p=0.002) and cardiovascular mortality (adjusted HR 2.23, 1.12-4.39, p=0.020) remained statistically significant.
Anaemia is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetic individuals, independently of the presence of CKD and other potential confounders. The advantage to treat anaemia in type 2 diabetes for reducing the risk of adverse cardiovascular outcomes remains to be demonstrated.
关于贫血是否是 2 型糖尿病心血管死亡率的危险因素,以及这种风险是否因慢性肾脏病(CKD)的存在而改变,目前相关信息有限且存在争议。我们评估了较低血红蛋白浓度对 2 型糖尿病患者全因和心血管死亡率的预测作用。
该队列包括 1153 名 2 型糖尿病门诊患者,平均随访 4.9 年。通过 Cox 比例风险回归模型评估贫血(即女性血红蛋白<120 g/l,男性血红蛋白<130 g/l)与全因和心血管死亡率的独立相关性,并调整了包括肾功能指标在内的几个潜在混杂因素。
随访期间,166 名(14.4%)患者死亡,其中 42.2%(n=70)死于心血管原因。在单因素分析中,贫血与全因死亡风险增加相关(风险比 HR 2.62,95%置信区间 1.90-3.60,p<0.001)和心血管死亡率(HR 2.70,1.67-4.37,p<0.001)。在校正年龄、性别、体重指数、吸烟、高血压、血脂异常、糖尿病病程、糖化血红蛋白、药物使用(降糖、降压、降脂和抗血小板药物)和肾功能指标后,贫血与全因死亡(调整后的 HR 2.11,1.32-3.35,p=0.002)和心血管死亡率(调整后的 HR 2.23,1.12-4.39,p=0.020)的相关性仍具有统计学意义。
贫血与 2 型糖尿病患者全因和心血管死亡率增加相关,与 CKD 及其他潜在混杂因素无关。治疗 2 型糖尿病贫血以降低不良心血管结局风险的益处仍有待证实。